Top Page
Sisram Medical Ltd.
(1696)
Sisram Medical Ltd. (1696) vs. iShares MSCI Hong Kong ETF (EWH)
Sisram Medical Ltd. Business Overview & Revenue Model
Sisram Medical Ltd. Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 349.11M | 359.29M | 354.48M | 294.29M | 162.09M |
| Gross Profit | 216.68M | 219.53M | 202.23M | 166.86M | 90.30M |
| EBITDA | 38.91M | 53.43M | 58.38M | 55.96M | 28.19M |
| Net Income | 25.13M | 31.50M | 40.17M | 31.25M | 13.34M |
Balance Sheet | |||||
| Total Assets | 627.26M | 613.50M | 555.60M | 530.13M | 431.81M |
| Cash, Cash Equivalents and Short-Term Investments | 71.98M | 70.60M | 81.41M | 152.92M | 116.37M |
| Total Debt | 43.20M | 44.68M | 41.34M | 41.62M | 37.06M |
| Total Liabilities | 142.47M | 143.98M | 123.38M | 126.51M | 99.92M |
| Stockholders Equity | 464.03M | 452.31M | 430.87M | 402.18M | 331.89M |
Cash Flow | |||||
| Free Cash Flow | 30.38M | 35.37M | -42.28M | 29.41M | 16.46M |
| Operating Cash Flow | 33.08M | 43.94M | 22.04M | 32.38M | 25.74M |
| Investing Cash Flow | -6.59M | -32.99M | -52.11M | -46.77M | -33.51M |
| Financing Cash Flow | -16.11M | -20.97M | -17.85M | 55.78M | -12.21M |
Sisram Medical Ltd. Technical Analysis
Sisram Medical Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | HK$2.48B | 15.47 | 4.46% | 2.38% | -3.32% | -12.94% | |
72 Outperform | HK$3.88B | 34.31 | 3.87% | ― | 12.94% | 212.66% | |
62 Neutral | HK$5.87B | 18.36 | 10.38% | 1.37% | 25.18% | 55.79% | |
59 Neutral | HK$7.60B | 98.88 | 6.36% | ― | 3.42% | -70.82% | |
41 Neutral | HK$4.10B | -16.75 | -11.17% | ― | 29.25% | 9.02% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Sisram Medical Ltd. Corporate Events
Sisram Medical Ltd announced a strategic collaboration between its subsidiary, Alma Lasers Ltd, and renowned skin-care expert Jamie Sherrill, known as Nurse Jamie. This partnership aims to enhance consumer engagement and strengthen Alma’s leadership in aesthetic technologies by leveraging Sherrill’s expertise and influence to promote Alma’s flagship platforms globally, potentially increasing demand and growth opportunities for clinic partners worldwide.
The most recent analyst rating on (HK:1696) stock is a Buy with a HK$6.50 price target. To see the full list of analyst forecasts on Sisram Medical Ltd. stock, see the HK:1696 Stock Forecast page.
Sisram Medical Ltd has announced the launch of PixelPeel™, a new laser peel treatment designed for effective skin renewal with minimal downtime. Debuting in North America, this treatment uses Alma’s MotionSync™ technology for precise and safe exfoliation, enhancing skin texture and tone. The introduction of PixelPeel™ is expected to expand the market for Sisram’s existing systems and accelerate the adoption of their devices globally.
The most recent analyst rating on (HK:1696) stock is a Buy with a HK$6.50 price target. To see the full list of analyst forecasts on Sisram Medical Ltd. stock, see the HK:1696 Stock Forecast page.
Sisram Medical Ltd announced its interim results for the first half of 2025, reporting a slight decline in revenue by 1.9% to US$165.5 million compared to the same period in 2024. Despite this, the APAC region showed strong performance with a 17.6% increase in revenue, and the injectables line saw a significant growth of 218.1%. However, the company’s gross profit margin decreased by 2.4 percentage points, and adjusted net profit fell by 28.1%. The board decided not to declare an interim dividend for this period.
The most recent analyst rating on (HK:1696) stock is a Buy with a HK$6.50 price target. To see the full list of analyst forecasts on Sisram Medical Ltd. stock, see the HK:1696 Stock Forecast page.
Sisram Medical Ltd. has announced a final cash dividend of HKD 0.126 per share for the fiscal year ending December 31, 2024. The dividend will be subject to a 20% withholding tax as per Israeli Tax Ordinance, with the payment date set for September 9, 2025. Shareholders have the option to apply for a reduced tax rate under applicable tax treaties, although no such treaty exists between Israel and Hong Kong. This announcement reflects the company’s commitment to returning value to its shareholders while navigating the complexities of international tax regulations.
Sisram Medical Ltd has announced a final dividend of HK$0.126 per share for the year ending December 31, 2024, to be paid on or around September 9, 2025. Shareholders will be subject to a 20% withholding tax on the dividend, with provisions for reduced rates under applicable tax treaties, although no such treaty exists with Hong Kong.
Sisram Medical Ltd has announced that its board of directors will meet on August 20, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. The meeting will also consider the declaration of an interim dividend, which could impact the company’s financial distribution to shareholders.
Sisram Medical Ltd announced that the commercialization of its product, DAXXIFY® (DaxibotulinumtoxinA-lanm), in Mainland China is progressing steadily. The company is actively working on regulatory filings, market access, and building a professional team to support the product’s launch, expressing strong confidence in its market potential.
Sisram Medical Ltd has announced the launch of Universkin, an AI-powered personalized medical-grade skincare system, in the U.S. market through its subsidiary Alma Lasers Ltd. This product utilizes AI-assisted software to provide tailored skincare formulations, marking a significant step in personalized skincare treatment. The company anticipates that this launch will enhance its product portfolio, boost market competitiveness, and serve as a new revenue driver, setting the stage for a global rollout.
Sisram Medical Ltd has announced changes in the composition of its board committees, effective June 24, 2025. These changes involve the appointment of new members and chairpersons for the audit, remuneration, and nomination committees, potentially impacting the company’s governance and strategic direction.
Sisram Medical Ltd has announced the updated list of its board of directors and their roles, effective June 24, 2025. This update in leadership structure, including executive, non-executive, and independent non-executive directors, may influence the company’s strategic direction and governance, potentially impacting its stakeholders and market positioning.